Advertisement
Australia markets close in 7 minutes

  • ALL ORDS

    7,866.70
    -142.70 (-1.78%)
     

  • ASX 200

    7,616.80
    -135.70 (-1.75%)
     

  • AUD/USD

    0.6423
    -0.0022 (-0.34%)
     

  • OIL

    85.96
    +0.55 (+0.64%)
     

  • GOLD

    2,401.70
    +18.70 (+0.78%)
     

  • Bitcoin AUD

    97,802.47
    -4,128.19 (-4.05%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • AUD/EUR

    0.6048
    -0.0011 (-0.18%)
     

  • AUD/NZD

    1.0901
    -0.0007 (-0.06%)
     

  • NZX 50

    11,804.84
    -111.94 (-0.94%)
     

  • NASDAQ

    17,706.83
    -296.65 (-1.65%)
     

  • FTSE

    7,965.53
    -30.05 (-0.38%)
     

  • Dow Jones

    37,735.11
    -248.13 (-0.65%)
     

  • DAX

    18,026.58
    +96.26 (+0.54%)
     

  • Hang Seng

    16,333.02
    -267.44 (-1.61%)
     

  • NIKKEI 225

    38,499.49
    -733.31 (-1.87%)
     

Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021

Athenex, Inc.
·1-min read

BUFFALO, N.Y., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2021, on Thursday, November 4, 2021. Athenex’s management team will host a conference call and live audio webcast at 10:00 a.m. Eastern Time.

To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins:

Domestic: (855) 227-0567

International: (612) 979-9912

ADVERTISEMENT

Passcode: 7292300

The live conference call and replay can also be accessed via audio webcast here and on the Investor Relations section of the Company’s website under “Events and Presentations”, located at http://ir.athenex.com/.

About Athenex, Inc.

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) Cell therapy, and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. For more information, please visit www.athenex.com.

Athenex Contacts

Investors

Daniel Lang, MD
Athenex, Inc.
Email: danlang@athenex.com

Caileigh Dougherty
Athenex, Inc.
Email: cdougherty@athenex.com